Fapon Biopharma to Exhibit Innovative Platforms and Pipeline at BIO 2025
Fapon Biopharma, a pioneering biotechnology company dedicated to developing advanced therapies for cancer and autoimmune diseases, is set to make a significant impact at the upcoming BIO International Convention 2025, which will take place from June 16 to 19 at the Boston Convention Exhibition Center. The company, known for its innovative approach toward therapeutic antibodies and fusion proteins, will showcase its diverse pipeline and proprietary technology platforms at Booth #1851. This year, Fapon Biopharma will highlight its flagship product, FP008, a first-in-class immunocytokine currently undergoing Phase 1 trials. FP008 is designed specifically for patients with solid tumors who have not responded well to anti-PD-1 therapy, addressing a critical gap in current treatment options.
In addition to FP008, Fapon Biopharma will present several promising early-stage candidates aimed at treating oncology and autoimmune diseases. These include preclinical assets such as FP010, FP011, FPE021 targeting various cancer types and FPE022, FPE024 focusing on autoimmune conditions. The company emphasizes the importance of fostering collaborations and partnerships that can enhance its development and bring transformative therapies to market more rapidly.
Fapon Biopharma's innovative technology platforms will also be on display, demonstrating the company’s commitment to overcoming the complexities of drug development. The Bi/Tri-TCE platform is designed to create potent multi-specific antibodies for targeted cancer immunotherapy, addressing patients' diverse needs. The FILTEN™ platform offers a novel approach for generating IL-10M fusion proteins to overcome existing limitations and broaden their applications in treating both cancer and autoimmune diseases. The PROTiNb™ platform allows for targeting of previously